67 results about "Psychosis drug" patented technology

The present invention relates to the use of one or more cannabinoids in combination with one or more anti-psychotic medicaments for use in the prevention or treatment of psychosis and psychotic disorders. Preferably the one or more cannabinoids are taken from the group: cannabidiol (CBD); cannabidiolic acid (CBDA); tetrahydrocannbidivarin (THCV); tetrahydrocannbidivarinin acid (THCVA); cannabichromene (CBC); cannabichromenic acid (CBCA); cannabigerol (CBG) and cannabigerolic acid (CBGA). Preferably the anti-psychotic medication is an atypical anti-psychotic medication.

Methods of treating headache with antipsychotics are provided. A kit for treating headache is also provided, comprising an antipsychotic and a device for rapid delivery of the antipsychotic.

The present invention relates to a pharmaceutical composition comprising glycerol esters of a fatty acid, wherein the compositions are useful for the delivery of anti-psychotic drugs.

The present invention relates to an injectable, pharmaceutical composition comprising a C_1-6 alkyl ester of a C_10-20 fatty acid. In an embodiment, the fatty acid is ethyl oleate, isopropyl oleate, ethyl myristate, or isopropyl myristate. These compositions are useful for the delivery of anti-psychotic drugs.

New methods of treating schizophrenia and schizoaffective disorder by administration of pharmaceutical compositions comprising an antipsychotic compound and a VMAT2 inhibitor to a subject in need thereof are provided.

Disclosed herein is the use of N-desmethylclozapine (NDMC) and related compounds to treat a variety of neuropsychiatric diseases including psychosis. It is shown that NDMC and related compounds are agonists or partial agonists at D2 and D3 dopamine receptors and thus may be effective as a dopamine stabilizing agent, allowing it to be used to treat or provide reduced incidence of Extrapyramidal symptoms (EPS) and/or tardive dyskinesias (TD). Also disclosed is administering NDMC and related compounds in combination with other anti-psychotic agents.

The present invention provides a method for identifying a compound or a combination of compounds having a pharmacological behavior that qualifies it as a candidate for clinical development of a drug for treatment of a psychiatric disease or disorder, preferably schizophrenia. According to this method, a candidate drug is assessed for its ability to produce a biochemical profile, in either or both in vitro and in vivo test systems, which is similar to a unique reference biochemical profile obtained following treatments with drugs or drug combinations effective against both positive and negative symptoms of psychiatric diseases or disorders.

The present invention provides a method for identifying an agent to be tested for an ability to treat a psychotic disorder in a patient in need of such treatment. The invention provides a method for screening candidate drugs for anti-psychotic drug activity, preferably atypical anti-psychotic activity, comprising contacting cells or tissues with a candidate drug, determining levels of phosphorylation of the intracellular signaling proteins, DARPP-32, ERK1, ERK2 and CREB, in said cells or tissues and determining the pattern of the levels of phosphorylation of the proteins. The pattern of the levels of phosphorylation of DARPP-32, ERK1, ERK2 and CREB is, in certain embodiments, compared with the pattern of the levels of phosphorylation of DARPP-32, ERK1, ERK2 and CREB in the presence of an atypical anti-psychotic drug.

The invention relates to a medicine for treating schizophrenia, relating to a medicine composition for treating schizophrenia, in particular to a medicine for treating schizophrenia by using fossil, ore, Chinese animal medicine and Chinese herbal medicines as raw materials. The formula comprises the following components: raw keel, ochre, rhubarb, wrinkled gianthyssop, tabasheer, lapis chloriti, arisaema with bile, albizia bark, datura flower, japanese sweetflag, radix curcumae, radix bupleuri, eupatorium, burreed tuber, curcuma zedoary, poria with hostwood and magnet. The medicine has therapeutic effects on schizophrenia, is safe and effective, has quick effect-taking, high total effective rate, few side effects and low recurernce rate when matched with a low dose of antipsychotic for treating schizophrenia, and is low in price, convenient to carry and take, and especially suitable for long-term maintenance treatment in a recovery phase and a stable phase.

An intranasal drug product is provided including an antipsychotic drug, such as haloperidol, in sprayable solution in an intranasal metered dose sprayer. Also provided is a method of administering an antipsychotic drug, such as haloperidol, to a patient, including the step of delivering an effective amount of the antipsychotic drug to a patient intranasally using an intranasal metered dose sprayer. A method of treating a psychotic episode also is provided, the method including the step of delivering an antipsychotic drug, such as haloperidol, intranasally in an amount effective to control the psychotic episode.

The present invention comprises novel methods for the use of compositions comprising 7-keto DHEA for treating psychiatric conditions. These methods include administering an effective amount of a composition comprising 7-keto DHEA in an acceptable carrier, alone or in combination with other psychiatric drugs, such as analgesic agents, anticonvulsants, anti-anxiety agents, antidepressants, anti-panic agents, antipsychotic agents, bipolar agents, psychostimulants to reduce or ameliorate symptoms of a psychiatric condition. This method may be used alone or as an adjunctive treatment for treating a wide variety of psychiatric conditions such as stress disorders, anxiety disorders and depressive disorders.

The invention discloses a high-dispersity composition of low-dose drugs and a preparation method of the high-dispersity composition, aiming to solve the problem that existing preparation methods for the low-dose drugs cannot meet requirements on content uniformity and influences of parameter change amplification in the production process on physicochemical properties of the low-dose drugs are remarkable. The high-dispersity composition and the preparation method thereof have the advantages that the low-dose drugs are prepared by the twin-screw extrusion technology for the first time; Vitamin Danalogue drugs, glucocorticoid drugs, antipsychotics, antipyretic and analgesic drugs and other low-dose drugs are screened as research objects; preparation of solid preparations through a twin-screwextruder is studied deeply; the content uniformity meets requirements of the pharmacopeia.

The invention provides an antipsychotic drug related metabolism syndrome susceptible gene and an application thereof, and concretely relates to a use of a separate single-nucleotide polymorphism (SNP) site-containing polynucleotide or a detection reagent thereof in the preparation of kits for detecting antipsychotic drug related metabolism syndrome susceptibility. The SNP site in the polynucleotide corresponds to human chromosome 17p11.2 region (chr17:17708129(GRCh37/hg19)), rs11654081, C to T. The susceptibility of individuals to antipsychotic drug related metabolism syndrome can be judged in an adjuvant manner through detecting the gene and SNP, and a new approach is provided for diagnosis and corresponding treatment of the syndrome; and additionally, the discovery of the gene and the SNP also provides a new drug target for developing drugs for treating the related metabolism syndrome, and the gene and the SNP can be used as syndrome patient regression and prognosis molecule markers.

A novel assay method suitable for screening of novel antipsychotics wherein the drugs may be selected based on the differential internalization of the 5-HT2A receptor in neuronal and non-neuronal cell lines effect for it to predict the extrapyramidal symptoms that may be induced by an antipsychotic without having to carry out in vivo experiments.

The present invention relates to the use of 3-acetyl-7-oxo-dehydroepiandrosterone (7-keto DHEA) in the preparation of a medicament to treat or ameliorate psychiatric conditions. The present invention relates to methods of using compositions comprising 7-keto DHEA to treat or ameliorate psychiatric conditions. These methods include administering an effective amount of a composition comprising 7-keto DHEA in an acceptable carrier, alone or in combination with other psychiatric drugs to reduce or ameliorate symptoms of a psychiatric condition. This method may be used alone or as an adjunctive treatment for treating a wide variety of psychiatric conditions.